Zentalis Pharmaceuticals, Inc. (ZNTL) stock
Close on Nov 13, 2026Market cap $121.84MP/E –Yield –
Zentalis Pharmaceuticals, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$133.87M. At the latest close the market valued the company at $121.84M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $121.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.59
- Dividend yield
- –
- Free cash flow yield
- -109.87%
Fundamentals
- Revenue
- $0
- Net income
- -$141.67M
- EPS, diluted
- -$1.92
- Free cash flow
- -$133.87M
- Book value per share
- $2.42
- Diluted shares
- 85M
Trading
- Next earnings
- Mar 25, 2027 (estimated, after the close)
- Previous close
- $1.68
- Open
- $1.68
- Day's range
- $1.63 – $1.76
- Volume
- 1,300,089
- Average volume (20 days)
- 1,474,390
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.14
- 52-week range
- $1.28 – $6.95
- RSI (14 days)
- 32.0
- Volatility (1 year)
- 128.9%
- Relative volume
- 1.04×
- WACC
- 15.8%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZNTL | S&P 500 | Difference | ZNTL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -29.2% | -3.0% | −26.1 pts | ||
| 3 months | -59.0% | -2.8% | −56.3 pts | ||
| Year to date | +25.9% | +11.5% | +14.4 pts | ||
| 1 year | +28.8% | +13.5% | +15.3 pts | ||
| 3 years | -83.4% | +77.7% | −161.1 pts | -45.1% | +21.1% |
| 5 years | -97.8% | +72.6% | −170.4 pts | -53.4% | +11.5% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zentalis Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Zentalis Pharmaceuticals
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted cancer therapies. Its lead product candidate is azenosertib, an investigational, orally administered small-molecule WEE1 inhibitor designed to selectively halt DNA damage repair in tumor cells and induce cell death. The firm concentrates its clinical development efforts on oncology indications, particularly platinum-resistant ovarian cancer characterized by Cyclin E1 overexpression, while exploring applications in other solid tumors. Its target patient populations include individuals diagnosed with advanced ovarian malignancies and other solid tumors who have received prior therapies.
Company profile, executives and historyZentalis Pharmaceuticals stock: common questions
What is Zentalis Pharmaceuticals's stock price?
ZNTL closed at $1.70 on Nov 13, 2026, up 1.19% on the day. Over the past 52 weeks it traded between $1.28 and $6.95.
What is Zentalis Pharmaceuticals's market cap?
Zentalis Pharmaceuticals was worth $121.84M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ZNTL's P/E ratio?
Zentalis Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.92), so it has no meaningful P/E ratio.
How much revenue does Zentalis Pharmaceuticals make?
Zentalis Pharmaceuticals reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Zentalis Pharmaceuticals pay a dividend?
No. Zentalis Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Zentalis Pharmaceuticals report earnings next?
Zentalis Pharmaceuticals is expected to report Q4 FY2026 results on Mar 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ZNTL stock performed over the past year?
Including dividends, ZNTL returned +28.8% over the past year, against +13.5% for the S&P 500.
How many ZNTL shares are sold short?
5M shares were sold short at the latest FINRA report, 16.74% of the float, or 3.5 days of average trading volume.
Who are Zentalis Pharmaceuticals's competitors?
Companies most similar to Zentalis Pharmaceuticals by business, industry and size include PRLD, PYXS, NAMS, TNGX, VRDN.
See a number that looks wrong?